Rosiglitazone treatment enhances intracellular actin dynamics and glucose transport in hypertrophic adipocytes
Fryklund, Claes LU ; Morén, Björn LU
; Neuhaus, Mathis
LU
; Periwal, Vipul
and Stenkula, Karin G.
LU
(2022)
In Life Sciences
299.
- Abstract
Aims: To accommodate surplus energy, adipose tissue expands by increasing both adipose cell size (hypertrophy) and cell number (hyperplasia). Enlarged, hypertrophic adipocytes are known to have reduced insulin response and impaired glucose transport, which negatively influence whole-body glucose homeostasis. Rosiglitazone is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, known to stimulate hyperplasia and to efficiently improve insulin sensitivity. Still, a limited amount of research has investigated the effects of rosiglitazone in mature, hypertrophic adipocytes. Therefore, the objective of this study was to examine rosiglitazone's effect on insulin-stimulated glucose uptake in hypertrophic adipocytes. Main... (More)
Aims: To accommodate surplus energy, adipose tissue expands by increasing both adipose cell size (hypertrophy) and cell number (hyperplasia). Enlarged, hypertrophic adipocytes are known to have reduced insulin response and impaired glucose transport, which negatively influence whole-body glucose homeostasis. Rosiglitazone is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, known to stimulate hyperplasia and to efficiently improve insulin sensitivity. Still, a limited amount of research has investigated the effects of rosiglitazone in mature, hypertrophic adipocytes. Therefore, the objective of this study was to examine rosiglitazone's effect on insulin-stimulated glucose uptake in hypertrophic adipocytes. Main methods: C57BL/6J male mice were subjected to 2 weeks of high-fat diet (HFD) followed by 1 week of HFD combined with daily administration of rosiglitazone (10 mg/kg). Adipose cell-size distribution and gene expression were analysed in intact adipose tissue, and glucose uptake, insulin response, and protein expression were examined using primary adipocytes isolated from epididymal and inguinal adipose tissue. Key findings: HFD-feeding induced an accumulation of hypertrophic adipocytes, which was not affected by rosiglitazone-treatment. Still, rosiglitazone efficiently improved insulin-stimulated glucose transport without restoring insulin signaling or GLUT4 expression in similar-sized adipocytes. This improvement occurred concurrently with extracellular matrix remodelling and restored intracellular levels of targets involved in actin turnover. Significance: These results demonstrate that rosiglitazone improves glucose transport in hypertrophic adipocytes, and highlights the importance of the cytoskeleton and extracellular matrix as potential therapeutic targets.
(Less)
- author
- Fryklund, Claes
LU
; Morén, Björn
LU
; Neuhaus, Mathis
LU
; Periwal, Vipul
and Stenkula, Karin G.
LU
- organization
- publishing date
- 2022-06-15
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adipocytes, Adipose tissue, Cytoskeleton, Glucose transport, Insulin, PPARγ, Rosiglitazone
- in
- Life Sciences
- volume
- 299
- article number
- 120537
- publisher
- Elsevier
- external identifiers
-
- pmid:35398016
- scopus:85128338524
- ISSN
- 0024-3205
- DOI
- 10.1016/j.lfs.2022.120537
- language
- English
- LU publication?
- yes
- id
- 9fd6c492-6bff-4591-98bc-250006e1ddca
- date added to LUP
- 2022-06-17 15:59:37
- date last changed
- 2024-06-14 17:55:50
@article{9fd6c492-6bff-4591-98bc-250006e1ddca,
abstract = {{<p>Aims: To accommodate surplus energy, adipose tissue expands by increasing both adipose cell size (hypertrophy) and cell number (hyperplasia). Enlarged, hypertrophic adipocytes are known to have reduced insulin response and impaired glucose transport, which negatively influence whole-body glucose homeostasis. Rosiglitazone is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, known to stimulate hyperplasia and to efficiently improve insulin sensitivity. Still, a limited amount of research has investigated the effects of rosiglitazone in mature, hypertrophic adipocytes. Therefore, the objective of this study was to examine rosiglitazone's effect on insulin-stimulated glucose uptake in hypertrophic adipocytes. Main methods: C57BL/6J male mice were subjected to 2 weeks of high-fat diet (HFD) followed by 1 week of HFD combined with daily administration of rosiglitazone (10 mg/kg). Adipose cell-size distribution and gene expression were analysed in intact adipose tissue, and glucose uptake, insulin response, and protein expression were examined using primary adipocytes isolated from epididymal and inguinal adipose tissue. Key findings: HFD-feeding induced an accumulation of hypertrophic adipocytes, which was not affected by rosiglitazone-treatment. Still, rosiglitazone efficiently improved insulin-stimulated glucose transport without restoring insulin signaling or GLUT4 expression in similar-sized adipocytes. This improvement occurred concurrently with extracellular matrix remodelling and restored intracellular levels of targets involved in actin turnover. Significance: These results demonstrate that rosiglitazone improves glucose transport in hypertrophic adipocytes, and highlights the importance of the cytoskeleton and extracellular matrix as potential therapeutic targets.</p>}},
author = {{Fryklund, Claes and Morén, Björn and Neuhaus, Mathis and Periwal, Vipul and Stenkula, Karin G.}},
issn = {{0024-3205}},
keywords = {{Adipocytes; Adipose tissue; Cytoskeleton; Glucose transport; Insulin; PPARγ; Rosiglitazone}},
language = {{eng}},
month = {{06}},
publisher = {{Elsevier}},
series = {{Life Sciences}},
title = {{Rosiglitazone treatment enhances intracellular actin dynamics and glucose transport in hypertrophic adipocytes}},
url = {{http://dx.doi.org/10.1016/j.lfs.2022.120537}},
doi = {{10.1016/j.lfs.2022.120537}},
volume = {{299}},
year = {{2022}},
}